The Medicines and Healthcare products Regulatory Agency said the measures are intended to ensure fair distribution while supply issues are addressed, with pharmacies instructed to follow the temporary dispensing limits.
Acting Attorney General Todd Blanche stated that the rescheduling of marijuana 'allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.' This marks a significant shift in the federal approach to medical marijuana.
I was devastated. I had been able to get Zepbound for a $30 monthly copay and had lost 50 pounds in a year. The drug helped me focus on being a new mom and gaining strength at the gym, not just counting calories burned.
Acting Attorney General Todd Blanche announced the decision in a post on X, noting that the DOJ would immediately move state-licensed marijuana and FDA-approved marijuana products to Schedule III alongside Tylenol with codeine, ketamine, and steroids.
Congress has kept key drug assistance funding at $900.3 million annually since 2014. New enrollments for state programs jumped 30% from 2022 to 2024, in part because states cut off pandemic-era Medicaid assistance. As of January, at least 18 states have pulled back their Ryan White AIDS Drug Assistance Programs, known as ADAPs, in some way.
Pharmacy benefit managers (PBMs) are opaque intermediaries-and they are unpopular with figures including Mark Cuban, who told Fortune that the way they bargain over drug prices is absurd, something that would never happen at the very same pharmacies buying a package of Pringles potato-chip products.
The 340B program allows hospitals to buy outpatient drugs at steep discounts, with the purported purpose of helping them fund care for low-income and uninsured patients. The now-axed rebate model would have invited drugmakers to participate voluntarily in a rebate-based discount system. Basically, instead of the provider receiving a discount upfront at purchase, the 340B discount would be applied after purchase via rebate - and subject to tedious data submission requirements.
The IRA requires drugmakers to sell selected patented drugs to the government for its Medicare Parts B & D programs at a stipulated "maximum fair price". If they don't agree to these prices, then they face tax penalties on sales of the drug exceeding their profits from it, or the exclusion of all their drugs from Medicare and Medicaid purchases. This would foreclose access to up to 160 million patients, accounting for around 40% of US prescription drug spending or 20% of global prescription drug spending.
For years, Congress has signaled that it wants to crack down on Pharmacy Benefit Managers, the middle men that have come under fire for their vertical integration with insurers and their role in spiking drug costs. This week, it finally happened via the Consolidated Appropriations Act of 2026, promptingemployer groups including the Purchaser Business Group on Health (PBGH) and the ERISA Industry Committee to cheer its passage.
The U.S. Food and Drug Administration is reportedly mulling whether more prescription drugs should be sold over the counter (OTC) at pharmacies. In an interview on Wednesday, FDA commissioner Martin Makary told CNBC that everything should be over the counter except drugs that are deemed unsafe or addictive or that require clinical monitoring. Makary said the agency is reviewing how it decides which drugs can be sold with or without a prescription from a health care practitioner.
